• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Keros Therapeutics Inc (NQ: KROS )

    49.57 -1.25 (-2.46%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 187,714
    Open 50.30
    Bid (Size) 49.50 (9)
    Ask (Size) 49.57 (2)
    Prev. Close 50.82
    Today's Range 48.97 - 51.26
    52wk Range 27.02 - 73.00
    Shares Outstanding 23,337,862
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
    Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation. Oppenheimer rates KROS Outperform with a $102 price target. 
    Via Benzinga
    KROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024
    KROS stock results show that Keros Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +14.93%
    +14.93%
    1 Month
    +6.65%
    +6.65%
    3 Month
    -10.18%
    -10.18%
    6 Month
    -11.02%
    -11.02%
    1 Year
    +15.25%
    +15.25%

    More News

    Read More
    Keros Therapeutics Inc. (NASDAQ: KROS) Near the Top of Equities by Percentage Gain on 1/4
    Via Investor Brand Network
    Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Where Keros Therapeutics Stands With Analysts
    Via Benzinga
    Recap: Keros Therapeutics Q1 Earnings
    Via Benzinga
    Recap: Keros Therapeutics Q3 Earnings
    Via Benzinga
    Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Keros Therapeutics Posts Preliminary Data Early-Stage KER-012 Trial
    Via Benzinga
    Keros Therapeutics Posts Encouraging Preclinical Data Of RKER-012 In Type Of High Blood Pressure
    Via Benzinga
    Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023
    Via Benzinga
    Why American Software Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Why Shares of Keros Therapeutics Jumped This Week
    Via The Motley Fool
    Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2023
    Via Benzinga
    BioMedNewsBreaks – Keros Therapeutics Inc. (NASDAQ: KROS) Presents Clinical and Preclinical Data from Its Lead Hematological Programs at 64th ASH Event
    Via Investor Brand Network
    Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
    Via Benzinga
    Why Shares of Keros Therapeutics Rose 10.2% This Week
    Via The Motley Fool
    Alphatec Holdings, Immatics And Some Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
    Via Benzinga
    76 Biggest Movers From Yesterday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.